Krystal Biotech
(NASDAQ) KRYS
Krystal Biotech Financials at a Glance
Market Cap
$11.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$417.30M
Net Income (TTM)
$225.03M
EPS (TTM)
$7.48
P/E Ratio
50.13
Dividend
$0.00
Beta (Volatility)
1.26 (Average)
Dividend
$0.00
Beta (Volatility)
1.26 (Average)
Price
$374.71
Volume
8,574
Open
$373.48
Price
$374.71
Volume
8,574
Open
$373.48
Previous Close
$374.71
Daily Range
$369.33 - $376.76
52-Week Range
$130.50 - $382.54
Estimated Earnings Date
Aug 3, 2026
Dividend
$0.00
Beta (Volatility)
1.26 (Average)
Price
$374.71
Volume
8,574
Open
$373.48
Previous Close
$374.71
Daily Range
$369.33 - $376.76
52-Week Range
$130.50 - $382.54
Estimated Earnings Date
Aug 3, 2026
KRYS News
KRYS: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Krystal Biotech
Industry
Biotechnology
Sector
Health CareEmployees
295
CEO
Krish S. Krishnan, MBA
Website
www.krystalbio.comHeadquarters
Pittsburgh, PA 15203, US
KRYS Financials
Key Financial Metrics (TTM)
Gross Margin
92.79%
Operating Margin
42.85%
Net Income Margin
53.92%
Return on Equity
19.25%
Return on Capital
13.13%
Return on Assets
16.11%
Earnings Yield
1.99%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$11.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
29.48M
Volume
8.57K
Avg. Volume
313.34K
Financials (TTM)
Gross Profit
$387.24M
Operating Income
$178.81M
EBITDA
$200.67M
Operating Cash Flow
$250.28M
Capital Expenditure
-$12.90M
Free Cash Flow
$237.38M
Cash & ST Invst.
$823.41M
Total Debt
$9.11M
Krystal Biotech Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$116.36M
+31.9%
Gross Profit
$110.03M
+32.3%
Gross Margin
94.57%
N/A
Market Cap
$11.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$40.21M
N/A
Employees
275
N/A
Net Income
$55.93M
+56.5%
EBITDA
$63.17M
+39.7%
Quarterly Fundamentals
Total Cash
$823.41M
+33.5%
Total Debt
$9.11M
-5.7%
Accounts Receivable
$127.02M
+23.0%
Inventory
$42.65M
+42.4%
Long Term Debt
$7.31M
-11.9%
Short Term Debt
$1.80M
+32.2%
Return on Assets
16.11%
N/A
Return on Invested Capital
13.87%
N/A
Free Cash Flow
$73.23M
+195.7%
Operating Cash Flow
$80.38M
+159.6%